Bridge Biotherapeutics and Pinotbio team up to develop cancer therapies using ADCs < Pharma < Article

Bridge Biotherapeutics said Thursday that it signed a memorandum of understanding (MOU) with Pinotbio to derive new cancer therapeutic candidates using antibody-drug conjugate (ADC) platform technology.

Bridge Biotherapeutics said Thursday that it signed a memorandum of understanding (MOU) with Pinotbio to derive new cancer therapeutic candidates using antibody-drug conjugate (ADC) platform technology.

Thus, Bridge Biotherapeutics will provide private anticancer targets and Pinotbio will provide ligands and applied drugs to its platform, PINOT-ADC, to continue the technology and information exchange for the next two years. According to the agreement, if new candidate materials are derived, the detailed conditions will lead to specified technology transfers and joint R&D contracts.

Bridge Biotherapeutics targets lung cancer therapeutics with EGFR C797S mutations that occur after the use of third-generation lung cancer drugs. Pinotbio has a third-generation ADC platform called Pinot-ADC, which has already successfully launched camtothecin-based drugs such as Daiichi Sankyo’s new ADC drug Enhertu (ingredient: trastuzumab deruxtecan) and Gilead’s Trodelvy (ingredient: sacituzumab govitecan ).

The platform has increased the possibility of overcoming resistant cancer cells through a dual mechanism of action, minimizing the impact of off-target drugs with its excellent pharmacokinetic profile.

In particular, Pinotbio proved equivalent safety and excellent anticancer efficacy in several preclinical comparison trials with Enhertu and Trodelvy, and published related data at the World ADC conference held last year.

“Following the development of lung cancer treatments through targeted anticancer methods, we will be actively examining the possibility of developing new treatment options in various cancers by combining ADC platforms,” ​​said Bridge Biotherapeutics CEO James Lee.

“We are pleased to sign an ADC development MOU with Bridge Biotherapeutics, which has sufficient business and clinical development organizations,” said Pinotbio CEO Jung Doo-young. “We look forward to merging this with our R&D expertise in targeted anticancer drugs in non-small cell lung cancer (NSCLC).”

Bridge Biotherapeutics and Pinotbio team up to develop cancer therapies using ADCs < Pharma < Article

Leave a Reply

Your email address will not be published.

Scroll to top